Rights and permissions
About this article
Cite this article
Ecallantide: final HAE patient treated in the second phase III trial. Inpharma Wkly. 1644, 11 (2008). https://doi.org/10.2165/00128413-200816440-00027
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200816440-00027